Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA’s REMS Reluctance On Display At Recent Advisory Committees

Jan 25 2019

• By Michael McCaughan

stopping the Dominio effect

Related Content

Sanofi's Sotagliflozin: Risk Of Ketoacidosis Divides US FDA Advisory Committee

Jan 18 2019

Uloric U-Turn: Gout Therapy Likely To Stay On Market Despite CV Safety Concern

Jan 18 2019

Evenity Likely Headed For Approval With Amgen's Proposed Indication, But Postmarketing Requirements Remain Unclear

Jan 17 2019

Is There A REMS In Uloric’s Future? US FDA Panelists Say Yes, Agency Says Not Likely

Jan 12 2019

Times Have Changed: FDA Ends ESA REMS Ahead Of First Biosimilars

Apr 17 2017

Related Companies

Takeda Pharmaceutical Co. Ltd.

Amgen, Inc.

UCB S.A.

Sanofi

Lexicon Pharmaceuticals, Inc.

Additional Topics

United States Drug Safety Risk Management Advisory Committees FDA Regulation BioPharmaceutical

More from Drug Safety

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window